Figure 5From: Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD (A) EFS by post induction CR/nCR; (B) OS of post-ASCT/nCR. Back to article page